Beijing Tiantan Biological Products Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Beijing Tiantan Biological Products kazanç ve gelirin sırasıyla yıllık 19.7% ve 19.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 20.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 14% olacağı tahmin edilmektedir.

Anahtar bilgiler

19.7%

Kazanç büyüme oranı

20.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	43.4%
Gelir büyüme oranı	19.6%
Gelecekteki özkaynak getirisi	14.0%
Analist kapsamı	Good
Son güncelleme	06 Nov 2024

Gelecekteki son büyüme güncellemeleri

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Oct 29

Recent updates

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Oct 29

Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth

Oct 27

Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)

Oct 08

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Sep 19

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Jul 23

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 09

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

May 22

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Mar 16

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Mar 01

Kazanç ve Gelir Büyüme Tahminleri

SHSE:600161 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	8,211	1,975	1,820	2,459	8
12/31/2025	7,131	1,648	1,589	2,510	7
12/31/2024	5,928	1,361	1,082	1,160	3
9/30/2024	5,232	1,274	270	1,351	N/A
6/30/2024	5,331	1,269	1,183	2,328	N/A
3/31/2024	5,110	1,165	1,087	2,242	N/A
12/31/2023	5,180	1,110	1,316	2,394	N/A
9/30/2023	5,371	1,167	1,254	2,515	N/A
6/30/2023	5,062	1,063	341	1,633	N/A
3/31/2023	4,848	1,018	250	1,539	N/A
12/31/2022	4,261	881	-228	1,126	N/A
9/30/2022	4,207	803	-195	1,097	N/A
6/30/2022	4,191	808	-187	1,117	N/A
3/31/2022	3,970	733	-351	918	N/A
12/31/2021	4,112	760	-151	980	N/A
9/30/2021	3,628	700	-241	728	N/A
6/30/2021	3,702	692	-120	640	N/A
3/31/2021	3,535	659	-71	571	N/A
12/31/2020	3,446	639	93	702	N/A
9/30/2020	3,398	641	306	755	N/A
6/30/2020	3,276	601	362	877	N/A
3/31/2020	3,334	611	184	741	N/A
12/31/2019	3,282	611	116	642	N/A
9/30/2019	3,394	580	282	788	N/A
6/30/2019	3,271	563	376	801	N/A
3/31/2019	3,083	531	729	1,028	N/A
12/31/2018	2,931	509	384	678	N/A
9/30/2018	2,929	568	538	767	N/A
6/30/2018	2,671	532	N/A	590	N/A
3/31/2018	2,485	1,228	N/A	186	N/A
12/31/2017	2,483	1,173	N/A	138	N/A
9/30/2017	2,362	1,077	N/A	301	N/A
6/30/2017	2,256	1,038	N/A	280	N/A
3/31/2017	2,330	313	N/A	344	N/A
12/31/2016	2,138	257	N/A	433	N/A
9/30/2016	1,756	151	N/A	251	N/A
6/30/2016	1,709	55	N/A	403	N/A
3/31/2016	1,624	-3	N/A	471	N/A
12/31/2015	1,618	10	N/A	473	N/A
9/30/2015	1,545	-88	N/A	384	N/A
6/30/2015	1,567	-46	N/A	382	N/A
3/31/2015	1,723	46	N/A	560	N/A
12/31/2014	1,827	128	N/A	478	N/A
9/30/2014	2,026	291	N/A	748	N/A
6/30/2014	2,018	377	N/A	705	N/A
3/31/2014	1,905	371	N/A	490	N/A
12/31/2013	1,837	372	N/A	566	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 600161 'nin tahmini kazanç büyümesi (yıllık 19.7% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 600161 şirketinin kazançlarının (yıllık 19.7% ) CN pazarından (yıllık 26.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 600161 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 600161 şirketinin gelirinin (yıllık 19.6% ) CN pazarından (yıllık 13.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 600161 şirketinin gelirinin (yıllık 19.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 600161 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 14 %).

Beijing Tiantan Biological Products Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Price target increased by 11% to CN¥33.90

Recent updates

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Dividend sustainability

Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)

Beijing Tiantan Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 23%

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Second quarter 2024 earnings: EPS misses analyst expectations

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 20%

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Price target increased by 11% to CN¥33.90

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

Now 21% overvalued after recent price rise

Now 27% overvalued

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd., Annual General Meeting, May 29, 2024

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.67 (vs CN¥0.53 in FY 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 3Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.075 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from S&P Global BMI Index

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from FTSE All-World Index (USD)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 3Q 2021)

Now 20% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.12 in 2Q 2021)

Now 20% undervalued

Now 21% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 2Q 2021)

Now 24% undervalued after recent price drop

Less than half of directors are independent

Now 20% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.17 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 1Q 2020)

New 90-day low: CN¥36.46

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.50

New 90-day high: CN¥41.95

Beijing Tiantan Biological Products Co., Ltd. announced that it expects to receive CNY 3.34 billion in funding

Third quarter earnings released

New 90-day low: CN¥37.99

First half earnings released

First half earnings released

New 90-day high - CN¥42.80

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin